CINITAPRIDE,PANTOPRAZOLE

Cinitapride and pantoprazole are gastroprotectant medications used in the treatment of gastroesophageal reflux disease (GERD) and non-ulcer dyspepsia.

Cinitapride, Pantoprazole, treats gastroesophageal reflux disease (GERD), in which the stomach acid and contents flow back into the esophagus. This capsule is also used to treat non-ulcer dyspepsia. It is a condition characterized by chronic pain or discomfort in the upper abdomen.

Take the Cinitapride and Pantoprazole as advised by your physician. Swallow the capsule whole and intact. This capsule should be taken with food. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the medicine if your doctor advises you to stop.

The side effects known to occur commonly during the treatment with Cinitapride, Pantoprazole are headache, nausea, diarrhea, abdominal pain, flatulence, constipation, rash, and dizziness. Some serious side effects also include swelling of the tongue or throat, difficulty in swallowing, breathing, allergic facial swelling, severe dizziness with heavy sweating, stomach pain or cramping, fever, joint pain or muscle weakness, and unusual tiredness or fatigue.

This drug is contraindicated in patients with tardive dyskinesia, a movement disorder condition associated with the long-term use of certain neuroleptic drugs. If a patient has a confirmed history of tardive dyskinesia related to the use of neuroleptics, this drug should be avoided. Also, hemorrhages, obstructions, or perforations are contraindications for using Cinitapride and Pantoprazole. These conditions involve structural abnormalities or severe damage to the gastrointestinal tract, and the increased gastric motility caused by this drug could worsen the situation or lead to further complications. Inform your doctor about the underlying issues, and they may provide some medical interventions to be followed.

Suppose an individual has a known history of allergic reactions or hypersensitivity to cinitapride or any of the ingredients used in the medication formulation. In that case, it should not be prescribed to them. If you suspect an allergic reaction, inform your healthcare provider before starting or continuing the medication. Cinitapride and Pantoprazole are not recommended for use during the first three months of pregnancy. If you suspect pregnancy or planning to become pregnant and have concerns about using this drug, it is highly advisable to discuss this with your healthcare provider.

Cinitapride and Pantoprazole should be taken with or after meals. Certain gastro-protectant medications demonstrate optimal efficacy when administered with food, which aids in protecting the stomach wall lining and reduces the risk of gastric irritation. Spicy foods, acidic foods, fatty or greasy foods, alcohol, and caffeine should be avoided. Adoption of a healthy lifestyle supports improved gastrointestinal health. This encompasses maintaining a balanced diet, regular physical exercise, stress management, adequate sleep, and avoiding excessive use of non-steroidal anti-inflammatory drugs (NSAIDs) unless prescribed by a healthcare professional.

Takeda UK Limited, Electronic Medicines Compendium (EMC), [Revised on April 2022] (Accessed on 26 May 2023), https://www.medicines.org.uk/emc/files/pil.484.pdf Cinitapride, National Center for Biotechnology Information. PubChem Compound Database. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Cinitapride#section=Drug-and-Medication-Information (Accessed on 26 May 2023). Cinita insert folded - getzpharma.com. Available at: https://getzpharma.com/wp-content/uploads/2016/07/Cinita-Tab-Leaflet-Pakistan.pdf (Accessed: 26 May 2023). Wyeth Pharmaceuticals LLC, US Food and Drug Administration, [Revised on Nov 2020] (Accessed on 26 May 2023), https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020987s056,022020s018lbl.pdf Bertram.G.Katzung, Basic and Clinical Pharmacology, Drugs Used in the Treatment of Gastrointestinal Diseases, 14th edition, 2017, 1091-1095.